Novo Nordisk submitted an oral version of the weight-loss formulation of semaglutide (Wegovy) for FDA approval, according to ...

Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...

Board Certified in Endocrinology, Diabetes, and Metabolism and Internal Medicine, Dr. Caveney leads IQVIA’s Obesity, ...

Plus, salon owners are seeing a massive drawdown in clients coming in for their regular scheduled appointments, citing ...

Eli Lilly suit against Houston’s Empower Pharmacy is a battle over access to a multi-billion dollar market for weight loss ...

Compounding pharmacies use active pharmaceutical ingredients – the part of the medication that produces therapeutic effects – ...

Discover Mounjaro Tirzepatide's impact on obesity in India post its March launch. Get insights on effectiveness against diabetes, hypertension & more.

As the FDA cracks down on compounded GLP-1 drugs like semaglutide and tirzepatide, the market for GLP-1 supplements is taking ...

Increased awareness and knowledge of GLP-1/GIP receptor agonists among women, with insights into public perspectives on ...

The latest discovery in obesity medicine will be available in less invasive creams and patches, known as transdermal drug ...

Americans spent an estimated $71.7 billion on GLP-1 drugs including Ozempic and Wegovy in 2023, a 500 percent increase from ...